The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.
My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...
A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common ...
(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...
Hosted on MSN3d
Regeneron makes second bid for blood cancer therapy approvalThe FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...
A remarkable start to the year, marked by a 160% surge, has had investors paying close attention to healthcare tech company ...
Beyond research, Germain concludes the conversation by providing helpful insights into the biggest challenges in lymphoma ...
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...
Hosted on MSN11d
Why Tempus AI (TEM) Crashed on Tuesday?In a statement, Tempus AI (NASDAQ:TEM) said it partnered with the Institute for Follicular Lymphoma Innovation (IFLI) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback